DGP Plc Takes Drug Testing In-house with Fingerprint Sweat-based Testing
22 Gennaio 2024 - 2:30PM
Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the
“Company”), a medical technology company delivering intelligent,
rapid, non-invasive testing solutions, today announced that DGP Plc
has selected the revolutionary portable Intelligent Fingerprinting
Drug Screening System to enable in-house drug testing.
DGP is one of the UK’s leading construction
logistics, security and support companies. Its services enable the
delivery of many of the country’s largest construction projects.
The company implements robust processes and risk-based SHEQ
management to support the way it delivers its works, and will now
use the Intelligent Fingerprinting Drug Screening System to enable
faster, more convenient and more flexible workplace drug
testing.
“Having already seen fingerprint sweat-based
drug screening in action at another company, I knew that the
Intelligent Fingerprinting would work well for DGP,” explained Ruth
Trant, DGP Plc’s SHEQ & Assurance Director. “We had previously
used an external drug testing service to carry out random
urine-based screening, but with around 450 employees and
contractors working on customer project sites at any one time, this
proved highly disruptive to productivity. With fingerprint
sweat-based testing we can conduct the ten-minute tests there and
then, with people not having to wait. The portability of the
Intelligent Fingerprinting system also means we can conduct
workplace testing wherever it is needed.
“We have a duty to put people to work safely,
and conducting testing sends a clear signal that coming to work
under the influence of drugs or alcohol is unsafe and not
acceptable at DGP Plc. We are also keen for everyone across the
business to see that we take our Drug and Alcohol Policy very
seriously. The fact that everyone in DGP is subject to random
testing is important, while its portability means that people get
to see our Intelligent Fingerprinting system in action regularly,”
added Ruth.
“An increasing number of construction and
logistics firms are turning to our fingerprint sweat-based system
for various testing needs, from recruitment and onboarding
requirements to random workplace screening or for cause testing,”
added Harry Simeonidis, President and Chief Executive Officer at
Intelligent Bio Solutions. “Our system’s flexibility and ease of
use makes it much simpler for organizations like DGP to manage
workplace drug testing internally, resulting in overall cost
savings and improved productivity due to minimal disruption.”
An introductory video demonstrating
fingerprint-based drug testing in action is available here.
About Intelligent Bio Solutions
Inc.
Intelligent Bio Solutions Inc. (the “Company”)
(Nasdaq: INBS) is a medical technology company delivering
intelligent, rapid, non-invasive testing solutions. The Company
believes that its Intelligent Fingerprinting Drug Screening System
will revolutionize portable testing through fingerprint sweat
analysis, which has the potential for broader applications in
additional fields. This hygienic and cost-effective system is
designed to screen for recent use of drugs commonly found in the
workplace, including opiates, cocaine, methamphetamine, and
cannabis. With sample collection in seconds and results in under
ten minutes, this technology would be a valuable tool for employers
in safety-critical industries. Additionally, the Company’s
biosensor platform has the potential to test for up to 130
indications, ranging from glucose to immunological conditions and
communicable diseases. The Company’s current customer segments
include construction, manufacturing and engineering, transport and
logistics firms, drug treatment organizations, and
coroners.
For more information,
visit: www.ibs.inc
About DGP Plc
DGP Plc is a leading UK construction logistics,
security, and support service contractor with an impressive track
record spanning over three decades. DGP has contributed to the
delivery of a range of complex and highly regulated projects across
the UK, including Manchester Airport, Paddington Square, Manchester
Old Town Hall, and Birmingham New Street Station.
For more information, visit: www.dgpplc.com
Forward-Looking Statements:
Some of the statements in this press release are
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, Section 21E of the Securities Exchange Act
of 1934 and the Private Securities Litigation Reform Act of 1995,
which involve risks and uncertainties. Forward-looking statements
in this press release include, without limitation, Intelligent Bio
Solutions Inc.’s ability to successfully develop and commercialize
its drug and diagnostic tests, realize commercial benefit from its
partnerships and collaborations, and secure regulatory approvals,
among others. Although Intelligent Bio Solutions Inc. believes that
the expectations reflected in such forward-looking statements are
reasonable as of the date made, expectations may prove to have been
materially different from the results expressed or implied by such
forward-looking statements. Intelligent Bio Solutions Inc. has
attempted to identify forward-looking statements by terminology,
including ”believes,” ”estimates,” ”anticipates,” ”expects,”
”plans,” ”projects,” ”intends,” ”potential,” ”may,” ”could,”
”might,” ”will,” ”should,” ”approximately” or other words that
convey uncertainty of future events or outcomes to identify these
forward-looking statements. These statements are only predictions
and involve known and unknown risks, uncertainties, and other
factors, included in Intelligent Bio Solutions’ public filings
filed with the Securities and Exchange Commission. Any
forward-looking statements contained in this release speak only as
of its date. Intelligent Bio Solutions undertakes no obligation to
update any forward-looking statements contained in this release to
reflect events or circumstances occurring after its date or to
reflect the occurrence of unanticipated events.
Company
Contact: Intelligent Bio Solutions
Inc. info@ibs.inc LinkedIn | Twitter
Media Contact: Cheryl
Billson, Comma Communications cheryl.billson@commacomms.com+44
(0)7791 720460
Grafico Azioni Intelligent Bio Solutions (NASDAQ:INBS)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Intelligent Bio Solutions (NASDAQ:INBS)
Storico
Da Set 2023 a Set 2024